<DOC>
	<DOC>NCT00965289</DOC>
	<brief_summary>A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.</brief_summary>
	<brief_title>High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma</brief_title>
	<detailed_description>Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and toxicity in 42 patients who underwent HDT with ASCT.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 18 to 60 y.o Aggressive Large BCell Lymphoma (CD20+) Ann Arbor stage III, IV IH or high adjusted IPI signed inform consent Age &lt; 18 ou &gt; 60 y.o other type of lymphoma serology VIH + other neoplasms apart from basal cell carcinoma or situ carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Aggressive large B-cell lymphoma (DLBCL)</keyword>
	<keyword>Intensive chemotherapy</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ASCT</keyword>
</DOC>